Italy's National Health Institute (ISS) has recommended that pregnant women should get COVID-19 vaccines after the first three months of their pregnancy, Reuters news agency reported on Friday.
The Italian health authority stated that it was advising women to receive two mRNA-based shots in the second and third trimesters of pregnancy.
According to the ISS, its decision was due to growing evidence on the safety of vaccines during pregnancies for both the foetus and the mother.
Women who are breastfeeding can safely get vaccinated, ISS adding, saying that infants can safely absorb antibodies via milk.
Italy is currently administering two vaccines based on messenger RNA (mRNA) technology, one made by BioNTech (Nasdaq:BNTX) in partnership with Pfizer (NYSE:PFE), and a second from Moderna Inc (Nasdaq:MRNA).
Merck launches Phase 3 trial for dengue vaccine candidate V181
BioNet and Bio Farma sign MoU on TdaP vaccine
Dx&Vx accelerates universal COVID-19 vaccine development
Moderna withdraws application for flu-COVID combination vaccine pending additional efficacy data
CTP delivers 18,000 sqm Serbian facility for SCHOTT Pharma to support global expansion
LakeShore Biopharma launches novel packaging solution for YSJA rabies vaccine (Vero cell)
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Orexo reports positive results for powder-based intranasal vaccine using AmorphOX technology
GC Biopharma's BARYTHRAX receives Korean regulatory approval
GSK grants USD2m to boost adult vaccination efforts
Valneva and LimmaTech begin Phase 2 infant trial for Shigella vaccine candidate S4V2
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100